Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients.
|
31548601 |
2020 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.
|
31633500 |
2020 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
|
31667572 |
2020 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibitors of CMIP could be used as potential adjuvant therapeutic drugs for HER2 positive gastric cancer.
|
31822364 |
2020 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited.
|
30365359 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer is a major challenge.
|
31423245 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
|
31587095 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
PD-L1 membrane expression on tumour cells (TC) and infiltrating immune cells (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, ATM and HER2 were assessed by immunohistochemistry (IHC) in the ACRG (Asian Cancer Research Group) GC cohort (N = 380).
|
30729066 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We aimed to evaluate whether HER2 expression in gastric cancer is affected by trastuzumab therapy.
|
30386954 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, intratumoral heterogeneity of HER2 expression is observed in 52% of metastatic GC cases.
|
31022472 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
We studied the plasma human epidermal growth factor receptor 2 (HER2) amplification in gastric cancer (GC) patients by droplet digital PCR (ddPCR) during therapy with trastuzumab.
|
30838039 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, d16HER2 may be considered as a "flag" of HER2 dependence in GC and can be clinically investigated as a marker of trastuzumab susceptibility in several other HER2-driven cancers, including CRC.
|
30837627 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers.
|
30597479 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
After phase III clinical trials, trastuzumab, anti-Erb-B2 receptor tyrosine kinase 2 (commonly known as ERBB2) and ramucirumab, anti-vascular endothelial growth factor receptor 2 (commonly known as VEGFR2) monoclonal antibodies, were approved and introduced into first- and second-line therapies for patients with advanced/metastatic GC.
|
31662821 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of our work was to address if pyrotinib treatment impacts the effect of HER2-positive GC cell-derived exosomes on endothelial cell (EC) progression.
|
31114227 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dual block HER2 assessment can effectively increase the HER2 positive rate in resected specimens of gastric cancer (GC).
|
31739285 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: CT-P6 (trastuzumab-pkrb, Herzuma) is a trastuzumab biosimilar approved for use in HER2 positive breast cancer and HER2 positive gastric cancer.
|
31507219 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The SNPs rs2643194, rs2934971, and rs1058808 of the ERBB2 gene were associated with increased risk for GC.
|
31116314 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings provide the basis for investigating the regulation of MAPK signaling pathways by HER2 and potential therapeutic targets for inhibiting metastasis and invasion in GC.
|
29734245 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
|
30927036 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Trastuzumab, an anti-human epidermal growth factor type 2 (HER2) monoclonal antibody, is effective in HER2-positive stomach cancer.
|
29992451 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive.
|
30348707 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
|
30442682 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer.
|
30857956 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial.
|
30463072 |
2019 |